Quick Answer
ARS Pharmaceuticals, Inc. reported Cash and Equivalents of $41.32 million for fiscal year 2025.
ARS Pharmaceuticals, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $41.32M | -18.7% |
| 2024 | $50.82M | -28.4% |
| 2023 | $70.97M | -66.3% |
| 2022 | $210.52M | +250.5% |
| 2021 | $60.06M | -84.5% |
| 2020 | $386.57M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $59.56M | +50.2% | +15.6% |
| June 30, 2025 | $51.54M | +40.7% | +29.3% |
| March 31, 2025 | $39.86M | -28.8% | -21.6% |
| December 31, 2024 | $50.82M | -28.4% | +28.1% |
| September 30, 2024 | $39.66M | -34.5% | +8.3% |
| June 30, 2024 | $36.63M | -69.2% | -34.6% |
| March 31, 2024 | $56.01M | -36.3% | -21.1% |
| December 31, 2023 | $70.97M | -66.3% | +17.2% |
- ARS Pharmaceuticals, Inc. showed a decrease of -18.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, ARS Pharmaceuticals, Inc.’s cash and equivalents has declined by 89.3% (from $386.57 million to $41.32 million).
- The most recent figure is from ARS Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: